Defying sporadic withdrawals of foreign companies and a perceived economic slowdown, AstraZeneca is adopting a “lean in” strategy in China with more locally developed drugs and wider outreach, Pascal Soriot, CEO of the Anglo-Swedish pharmaceuticals giant, told China Daily.
Tagrisso, the company’s latest drug for treating lung cancer with the EFGR-mutation, is expected to receive approval in China soon. The drug has been under fast-track review, because nearly half of Chinese lung cancer patients have this mutation.
